EP Patent

EP2485712A1 — Subcutaneous paliperidone composition

Assigned to Ascendis Pharma AS · Expires 2012-08-15 · 14y expired

What this patent protects

The present invention relates to pharmaceutical composition for subcutaneous injection comprising a paliperidone compound wherein the composition releases the paliperidone with an immediate onset of action and continuously for at least 3 weeks, and wherein the composition has a p…

USPTO Abstract

The present invention relates to pharmaceutical composition for subcutaneous injection comprising a paliperidone compound wherein the composition releases the paliperidone with an immediate onset of action and continuously for at least 3 weeks, and wherein the composition has a pharmacokinetic profile in vivo with substantially no burst release of the paliperidone. The compositios are useful as medicaments for the treatment of psychotic disorders and diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP2485712A1
Jurisdiction
EP
Classification
—
Expires
2012-08-15
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.